Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury

Naikui Liu, Yi Ping Zhang, Shu Han, Jiong Pei, Lisa Y. Xu, Pei Hua Lu, Christopher B. Shields, Xiao-Ming Xu

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Annexin A1 (ANXA1) has been suggested to be a mediator of the anti-inflammatory actions of glucocorticoids and more recently an endogenous neuroprotective agent. In the present study, we investigated the anti-inflammatory and neuroprotective effects of ANXA1 in a model of contusive spinal cord injury (SCI). Here we report that injections of ANXA1 (Ac 2-26) into the acutely injured spinal cord at 2 concentrations (5 and 20 μg) inhibited SCI-induced increases in phospholipase A2 and myeloperoxidase activities. In addition, ANXA1 administration reduced the expression of interleukin-1β and activated caspase-3 at 24 hours, and glial fibrillary acidic protein at 4 weeks postinjury. Furthermore, ANXA1 administration significantly reversed phospholipase A2-induced spinal cord neuronal death in vitro and reduced tissue damage and increased white matter sparing in vivo, compared to the vehicle-treated controls. Fluorogold retrograde tracing showed that ANXA1 administration protected axons of long descending pathways at 6 weeks post-SCI. ANXA1 administration also significantly increased the number of animals that responded to transcranial magnetic motor-evoked potentials. However, no measurable behavioral improvement was found after these treatments. These results, particularly the improvements obtained in tissue sparing and electrophysiologic measures, suggest a neuroprotective effect of ANXA1.

Original languageEnglish (US)
Pages (from-to)932-943
Number of pages12
JournalJournal of Neuropathology and Experimental Neurology
Volume66
Issue number10
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Annexin A1
Annexins
Phospholipases A2
Spinal Cord Injuries
Neuroprotective Agents
Spinal Cord
Anti-Inflammatory Agents
Motor Evoked Potentials
Glial Fibrillary Acidic Protein
Interleukin-1
Caspase 3
Glucocorticoids
Peroxidase
Axons
Injections

Keywords

  • Annexin A1
  • Inflammation
  • Neuroprotection
  • Phospholipase A
  • Spinal cord injury

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Neuroscience(all)

Cite this

Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury. / Liu, Naikui; Zhang, Yi Ping; Han, Shu; Pei, Jiong; Xu, Lisa Y.; Lu, Pei Hua; Shields, Christopher B.; Xu, Xiao-Ming.

In: Journal of Neuropathology and Experimental Neurology, Vol. 66, No. 10, 10.2007, p. 932-943.

Research output: Contribution to journalArticle

@article{54385f648d5447ebbda0db83fa3cae06,
title = "Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury",
abstract = "Annexin A1 (ANXA1) has been suggested to be a mediator of the anti-inflammatory actions of glucocorticoids and more recently an endogenous neuroprotective agent. In the present study, we investigated the anti-inflammatory and neuroprotective effects of ANXA1 in a model of contusive spinal cord injury (SCI). Here we report that injections of ANXA1 (Ac 2-26) into the acutely injured spinal cord at 2 concentrations (5 and 20 μg) inhibited SCI-induced increases in phospholipase A2 and myeloperoxidase activities. In addition, ANXA1 administration reduced the expression of interleukin-1β and activated caspase-3 at 24 hours, and glial fibrillary acidic protein at 4 weeks postinjury. Furthermore, ANXA1 administration significantly reversed phospholipase A2-induced spinal cord neuronal death in vitro and reduced tissue damage and increased white matter sparing in vivo, compared to the vehicle-treated controls. Fluorogold retrograde tracing showed that ANXA1 administration protected axons of long descending pathways at 6 weeks post-SCI. ANXA1 administration also significantly increased the number of animals that responded to transcranial magnetic motor-evoked potentials. However, no measurable behavioral improvement was found after these treatments. These results, particularly the improvements obtained in tissue sparing and electrophysiologic measures, suggest a neuroprotective effect of ANXA1.",
keywords = "Annexin A1, Inflammation, Neuroprotection, Phospholipase A, Spinal cord injury",
author = "Naikui Liu and Zhang, {Yi Ping} and Shu Han and Jiong Pei and Xu, {Lisa Y.} and Lu, {Pei Hua} and Shields, {Christopher B.} and Xiao-Ming Xu",
year = "2007",
month = "10",
doi = "10.1097/nen.0b013e3181567d59",
language = "English (US)",
volume = "66",
pages = "932--943",
journal = "American Journal of Psychotherapy",
issn = "0002-9564",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Annexin A1 reduces inflammatory reaction and tissue damage through inhibition of phospholipase A2 activation in adult rats following spinal cord injury

AU - Liu, Naikui

AU - Zhang, Yi Ping

AU - Han, Shu

AU - Pei, Jiong

AU - Xu, Lisa Y.

AU - Lu, Pei Hua

AU - Shields, Christopher B.

AU - Xu, Xiao-Ming

PY - 2007/10

Y1 - 2007/10

N2 - Annexin A1 (ANXA1) has been suggested to be a mediator of the anti-inflammatory actions of glucocorticoids and more recently an endogenous neuroprotective agent. In the present study, we investigated the anti-inflammatory and neuroprotective effects of ANXA1 in a model of contusive spinal cord injury (SCI). Here we report that injections of ANXA1 (Ac 2-26) into the acutely injured spinal cord at 2 concentrations (5 and 20 μg) inhibited SCI-induced increases in phospholipase A2 and myeloperoxidase activities. In addition, ANXA1 administration reduced the expression of interleukin-1β and activated caspase-3 at 24 hours, and glial fibrillary acidic protein at 4 weeks postinjury. Furthermore, ANXA1 administration significantly reversed phospholipase A2-induced spinal cord neuronal death in vitro and reduced tissue damage and increased white matter sparing in vivo, compared to the vehicle-treated controls. Fluorogold retrograde tracing showed that ANXA1 administration protected axons of long descending pathways at 6 weeks post-SCI. ANXA1 administration also significantly increased the number of animals that responded to transcranial magnetic motor-evoked potentials. However, no measurable behavioral improvement was found after these treatments. These results, particularly the improvements obtained in tissue sparing and electrophysiologic measures, suggest a neuroprotective effect of ANXA1.

AB - Annexin A1 (ANXA1) has been suggested to be a mediator of the anti-inflammatory actions of glucocorticoids and more recently an endogenous neuroprotective agent. In the present study, we investigated the anti-inflammatory and neuroprotective effects of ANXA1 in a model of contusive spinal cord injury (SCI). Here we report that injections of ANXA1 (Ac 2-26) into the acutely injured spinal cord at 2 concentrations (5 and 20 μg) inhibited SCI-induced increases in phospholipase A2 and myeloperoxidase activities. In addition, ANXA1 administration reduced the expression of interleukin-1β and activated caspase-3 at 24 hours, and glial fibrillary acidic protein at 4 weeks postinjury. Furthermore, ANXA1 administration significantly reversed phospholipase A2-induced spinal cord neuronal death in vitro and reduced tissue damage and increased white matter sparing in vivo, compared to the vehicle-treated controls. Fluorogold retrograde tracing showed that ANXA1 administration protected axons of long descending pathways at 6 weeks post-SCI. ANXA1 administration also significantly increased the number of animals that responded to transcranial magnetic motor-evoked potentials. However, no measurable behavioral improvement was found after these treatments. These results, particularly the improvements obtained in tissue sparing and electrophysiologic measures, suggest a neuroprotective effect of ANXA1.

KW - Annexin A1

KW - Inflammation

KW - Neuroprotection

KW - Phospholipase A

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=34948894950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948894950&partnerID=8YFLogxK

U2 - 10.1097/nen.0b013e3181567d59

DO - 10.1097/nen.0b013e3181567d59

M3 - Article

C2 - 17917587

AN - SCOPUS:34948894950

VL - 66

SP - 932

EP - 943

JO - American Journal of Psychotherapy

JF - American Journal of Psychotherapy

SN - 0002-9564

IS - 10

ER -